IDL Biotech
IDL Biotech: Q2 Review (Redeye)

2020-07-23 16:41
Redeye gives its comment on IDL’s Q2 report. As estimated in our previous research note, the quarter saw a significant sales drop owing to down-priorities with the corona crisis. IDL guides for a better third quarter and we find it reasonable that FY 2020 sales could reach our forecasted SEK ~30 million, which would represent only a slight decrease in sales compared to last year’s figures. In this note, we share our impressions of the report, as well as our view on CEO Charlotte Berg’s resignation.

info@redeye.se (Redeye.se)
Redeye AB - Redeye.se

Marknadsöversikt

Stockholmsbörsen, OMXS30

I dag
-
Senast
-
{point.key}

Världsindex

Index +/- % Senast
DAX - -
Hang Seng - -
Nikkei - -

Valutor

Valuta +/- % Senast
USD/SEK - -
EUR/SEK - -
GBP/SEK - -
EUR/USD - -

Räntor

Ränta +/- % Senast
5-års ränta - -
10-års ränta - -

Råvaror

Råvara +/- % Senast
Guld - -
Silver - -
Koppar - -